Bio-Thera Collaborates with Gedeon Richter for BAT2206 (Biosimilar, Stelara)
Shots:
- Bio-Thera has entered into an exclusive commercialization and licensing agreement with Gedeon Richter for BAT2206, a biosimilar version of Stelara (ustekinumab)
- Bio-Thera will handle development, manufacturing & supply of BAT2206 while Richter will have exclusive commercialization rights across the EU, UK, Switzerland & selected regions. Bio-Thera has already submitted regulatory filing with the EMA in Jul 2024
- Gedeon Richter will pay $8.5M upfront as well as ~$101.5M development & commercial milestones, contingent on meeting certain conditions
Ref: PR Newswire | Image: Bio-Thera and Gedeon Richter
Related News:- Bio-Thera Solutions Expands its Partnership with Pharmapark for BAT2306 (Biosimilar, Cosentyx) Across Russia and Other Countries
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
